{"id":"W2566964764","doi":"10.1182/blood.v112.11.3706.3706","title":"A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Lenalidomide; Refractory (planetary science); Neutropenia; Oncology; Pharmacology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002224137,0.002009579,0.002283055,0.0006807568,0.0005584531,0.001031321,0.001319349,0.001518727,0.004123835],"category_scores_gemma":[0.0009740188,0.0007929156,0.001174275,0.0006464968,0.0008988197,0.0008482489,0.0005311197,0.004036939,0.001212757],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001471409,"about_ca_system_score_gemma":0.00172284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001403093,"about_ca_topic_score_gemma":0.003006496,"domain_scores_codex":[0.9993486,0.0003031697,0.00003867446,0.0001056524,0.00007098859,0.0001329007],"domain_scores_gemma":[0.9991735,0.00008362126,0.0001388003,0.00007097921,0.00004464895,0.0004884999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6653038,0.1136989,0.009218971,0.001008416,0.001609705,0.0008723627,0.0003855382,0.004181947,0.0777352,0.0005574116,0.01086872,0.1145591],"study_design_scores_gemma":[0.6299114,0.3524878,0.008629537,0.00003612315,0.000405473,0.0004861275,0.00002917382,0.001093105,0.003963382,0.0001650321,0.002765316,0.00002760145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835517,0.002733235,0.0007721254,0.001383876,0.000223065,0.005032524,0.001672172,0.0002247341,0.004406713],"genre_scores_gemma":[0.9808261,0.001683531,0.004075603,0.001493522,0.0003706399,0.004351783,0.003551105,0.00004008943,0.003607622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004123835,"threshold_uncertainty_score":0.01379561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.130523716141316,"score_gpt":0.3844697312099192,"score_spread":0.2539460150686031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}